Skip to content

PLIN3 knockdown enhances T cell-mediated cytotoxicity in non-small cell lung cancer via autophagy-dependent PD-L1 degradation.

Jul 2026 · International Immunopharmacology · Vol 187, pp. 117179 · 0 citations · 37 references
Medicine

TL;DR

It is shown that targeting PLIN3 can induce autophagy, which promotes the degradation of PD-L1, ultimately leading to enhanced activation of T cells and an innovative approach to enhance the efficacy of immunotherapy in lung cancer.

Abstract

Background

Recently, immune checkpoint inhibitors (ICIs), especially those that targets PD-1/PD-L1, have significantly altered the treatment approach for NSCLC. Nevertheless, many patients experience different levels of resistance after receiving treatment with ICIs, which restrict their broader use in clinical practice. Therefore, to enhance the overall efficacy of ICIs, there is an immediate necessity to further explain the processes of immune evasion in NSCLC, especially the modulatory mechanism of PD-L1.

Methods

IHC was used to evaluate the protein expression level of PLIN3 and PD-L1 in NSCLC tissues. The impact of PLIN3 on PD-L1 was analyzed in NCI-H1975 and NCI-H157 cells using western blot, flow cytometry and quantitative PCR (qPCR). Immunofluorescence was performed to examine the effect of PLIN3 on the autophagy level. The levels of Granzyme B (GZMB) and interferon-gamma (IFN-γ) secreted by T cell were assessed. Bioinformatic analyses, including immune infiltration estimation and TIDE score, were performed using TCGA data.

Results

In this research, we discovered that elevated PLIN3 level was linked to decreased infiltration of CD4+ and CD8+ T cell, a higher TIDE score, and poorer immunotherapy response. In NSCLC tissues, there was a positive correlation between PLIN3 and PD-L1. Besides, the level of PLIN3 protein is significantly reduced in patients who achieve pathological complete response. In addition, PLIN3 knockdown markedly reduced the level of PD-L1 protein. Mechanistically, PLIN3 knockdown activated autophagy, and promoted PD-L1 degradation via the autophagic-lysosomal pathway, which consequently shortened its protein half-life. Furthermore, PLIN3 knockdown enhanced T-cell-mediated tumor killing and resulted in an increased secretion of the effector molecules, including granzyme B and IFN-γ.

Conclusions

In summary, our study has shown that targeting PLIN3 can induce autophagy, which promotes the degradation of PD-L1, ultimately leading to enhanced activation of T cells. This research is the first to investigate the function of PLIN3 in the immune microenvironment, revealing its critical function in immune evasion and highlighting its promise as a treatment target. This offers an innovative approach to enhance the efficacy of immunotherapy in lung cancer.

View source

Similar papers

Open access Aug 2026

Exploration of the regulatory mechanism of PD-L1 expression in pMMR AGS gastric cancer cell by cytotoxic drugs and anti-angiogenic drugs

Immune checkpoint inhibitors (ICIs) play a key role in treating advanced gastric cancer; however, their efficacy is limited in patients with proficient mismatch repair (pMMR) tumors. Therefore, enhancing ICIs sensitivity in this subgroup is crucial. Preclinical studies have indicated that cytotoxic and anti-angiogeni...

Jinming Li, M. Da, Xue-Ying Zhou et al. · 0 citations
Jul 2026

The role of the transcription factor Blimp-1 in T cells in anti-PD1 immunotherapy in non-small cell lung cancer 2258857

Immune checkpoint inhibitors targeting the interaction between PD1 and PDL1 are effective for immunotherapy in non-small cell lung cancer (NSCLC), which is the leading cause of cancer related death in the world. However, only subgroups of patients respond to therapy suggesting the existence of resistance mechanis...

S. Finotto, M. Chiriac, Susanne Krammer et al. · 0 citations
Aug 2026

Targeting ERO1A enhances antitumor immune response by recruiting CD8+T cells and synergizing with PD-L1 blockade in liver cancer.

Despite the availability of various treatment modalities for liver cancer, its mortality rate remains high. Immunotherapy represents an emerging approach for liver cancer. However, the response rate to single-agent immune checkpoint blockade therapy is suboptimal. Endoplasmic reticulum oxidoreductase 1-alpha (ERO1A), a...

Jing Mao, Xu Sun, Cai-Yun Chu et al. · 0 citations
2026

LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of immune checkpoint proteins in HCC with python analysis

Objective(s): Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with limited treatment options, particularly in advanced stages. Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 have shown promise in cancer immunotherapy, but response rates in HCC remain variable. Materials and Metho...

Masoud Khodarahmi, Danial Amiri Manjili, Foroozan Yarahmadi et al. · 0 citations
Open access Aug 2026

Berberine induces PD-L1 degradation via the autophagy-lysosome pathway through the PI3K-Akt pathway and enhances immunogenic cell death in triple-negative breast cancer

Objective This study aimed to investigate the regulatory effect and molecular mechanism of Berberine (BBR) on programmed death-ligand 1 (PD-L1) expression in Triple-Negative Breast Cancer (TNBC) cells. Methods In vitro cellular experiments (using MDA-MB-231 and BT-549 cell lines) and mouse models (Balb/c-nu and Balb/c...

Yuqin Wei, Qiudan Huang, Xin Wei et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.